Dynavax Technologies Corporation

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, TAK has a market cap of 59.4B. Regarding current trading prices, DVAX is priced at $15.50, while TAK trades at $18.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas TAK's P/E ratio is 81.72. In terms of profitability, DVAX's ROE is -0.08%, compared to TAK's ROE of +0.02%. Regarding short-term risk, DVAX is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check TAK's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ZTS has a market cap of 55.4B. Regarding current trading prices, DVAX is priced at $15.50, while ZTS trades at $127.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ZTS's P/E ratio is 20.93. In terms of profitability, DVAX's ROE is -0.08%, compared to ZTS's ROE of +0.58%. Regarding short-term risk, DVAX is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ZTS's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, HLN has a market cap of 49.9B. Regarding current trading prices, DVAX is priced at $15.50, while HLN trades at $11.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas HLN's P/E ratio is 24.07. In terms of profitability, DVAX's ROE is -0.08%, compared to HLN's ROE of +0.15%. Regarding short-term risk, DVAX is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check HLN's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, TEVA has a market cap of 38.9B. Regarding current trading prices, DVAX is priced at $15.50, while TEVA trades at $34.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas TEVA's P/E ratio is 28.03. In terms of profitability, DVAX's ROE is -0.08%, compared to TEVA's ROE of +0.20%. Regarding short-term risk, DVAX is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check TEVA's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, VTRS has a market cap of 18.4B. Regarding current trading prices, DVAX is priced at $15.50, while VTRS trades at $15.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas VTRS's P/E ratio is -5.10. In terms of profitability, DVAX's ROE is -0.08%, compared to VTRS's ROE of -0.23%. Regarding short-term risk, DVAX is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check VTRS's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, DVAX is priced at $15.50, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ITCI's P/E ratio is -180.64. In terms of profitability, DVAX's ROE is -0.08%, compared to ITCI's ROE of -0.04%. Regarding short-term risk, DVAX and ITCI have similar daily volatility (0.00).Check ITCI's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, RGC has a market cap of 13.3B. Regarding current trading prices, DVAX is priced at $15.50, while RGC trades at $33.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas RGC's P/E ratio is -2699.00. In terms of profitability, DVAX's ROE is -0.08%, compared to RGC's ROE of -0.62%. Regarding short-term risk, DVAX is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check RGC's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, NBIX has a market cap of 12.9B. Regarding current trading prices, DVAX is priced at $15.50, while NBIX trades at $130.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas NBIX's P/E ratio is 27.49. In terms of profitability, DVAX's ROE is -0.08%, compared to NBIX's ROE of +0.17%. Regarding short-term risk, DVAX is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check NBIX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ELAN has a market cap of 12.3B. Regarding current trading prices, DVAX is priced at $15.50, while ELAN trades at $25.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ELAN's P/E ratio is 353.50. In terms of profitability, DVAX's ROE is -0.08%, compared to ELAN's ROE of +0.01%. Regarding short-term risk, DVAX is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ELAN's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, RDY has a market cap of 12.2B. Regarding current trading prices, DVAX is priced at $15.50, while RDY trades at $14.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas RDY's P/E ratio is 19.59. In terms of profitability, DVAX's ROE is -0.08%, compared to RDY's ROE of +0.16%. Regarding short-term risk, DVAX is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check RDY's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, DVAX is priced at $15.50, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas CTLT's P/E ratio is -27.84. In terms of profitability, DVAX's ROE is -0.08%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, DVAX is less volatile compared to CTLT. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check CTLT's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, LNTH has a market cap of 5B. Regarding current trading prices, DVAX is priced at $15.50, while LNTH trades at $73.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas LNTH's P/E ratio is 30.46. In terms of profitability, DVAX's ROE is -0.08%, compared to LNTH's ROE of +0.15%. Regarding short-term risk, DVAX is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check LNTH's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, AMRX has a market cap of 4.5B. Regarding current trading prices, DVAX is priced at $15.50, while AMRX trades at $14.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas AMRX's P/E ratio is 1442.00. In terms of profitability, DVAX's ROE is -0.08%, compared to AMRX's ROE of -0.05%. Regarding short-term risk, DVAX is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check AMRX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, INDV has a market cap of 4.1B. Regarding current trading prices, DVAX is priced at $15.50, while INDV trades at $34.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas INDV's P/E ratio is 33.60. In terms of profitability, DVAX's ROE is -0.08%, compared to INDV's ROE of -0.60%. Regarding short-term risk, DVAX is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check INDV's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, SUPN has a market cap of 2.9B. Regarding current trading prices, DVAX is priced at $15.50, while SUPN trades at $51.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas SUPN's P/E ratio is -149.09. In terms of profitability, DVAX's ROE is -0.08%, compared to SUPN's ROE of -0.02%. Regarding short-term risk, DVAX is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check SUPN's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, DVAX is priced at $15.50, while HCM trades at $15.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas HCM's P/E ratio is 5.72. In terms of profitability, DVAX's ROE is -0.08%, compared to HCM's ROE of +0.47%. Regarding short-term risk, DVAX is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check HCM's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, BHC has a market cap of 2.2B. Regarding current trading prices, DVAX is priced at $15.50, while BHC trades at $5.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas BHC's P/E ratio is 6.18. In terms of profitability, DVAX's ROE is -0.08%, compared to BHC's ROE of -0.21%. Regarding short-term risk, DVAX is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check BHC's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, DVAX is priced at $15.50, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas DCPH's P/E ratio is -11.58. In terms of profitability, DVAX's ROE is -0.08%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, DVAX is less volatile compared to DCPH. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check DCPH's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, DVAX is priced at $15.50, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, DVAX's ROE is -0.08%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, DVAX and AVDL have similar daily volatility (0.00).Check AVDL's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, PAHC has a market cap of 2.1B. Regarding current trading prices, DVAX is priced at $15.50, while PAHC trades at $51.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas PAHC's P/E ratio is 22.80. In terms of profitability, DVAX's ROE is -0.08%, compared to PAHC's ROE of +0.31%. Regarding short-term risk, DVAX is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check PAHC's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, DVAX is priced at $15.50, while PRGO trades at $14.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas PRGO's P/E ratio is -69.33. In terms of profitability, DVAX's ROE is -0.08%, compared to PRGO's ROE of -0.01%. Regarding short-term risk, DVAX is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check PRGO's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, HROW has a market cap of 1.9B. Regarding current trading prices, DVAX is priced at $15.50, while HROW trades at $50.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas HROW's P/E ratio is -396.54. In terms of profitability, DVAX's ROE is -0.08%, compared to HROW's ROE of -0.09%. Regarding short-term risk, DVAX is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check HROW's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, DVAX is priced at $15.50, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas EMBCV's P/E ratio is N/A. In terms of profitability, DVAX's ROE is -0.08%, compared to EMBCV's ROE of -0.28%. Regarding short-term risk, DVAX is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check EMBCV's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, DVAX is priced at $15.50, while ANIP trades at $78.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ANIP's P/E ratio is 46.94. In terms of profitability, DVAX's ROE is -0.08%, compared to ANIP's ROE of +0.08%. Regarding short-term risk, DVAX is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ANIP's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, DVAX is priced at $15.50, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas TARO's P/E ratio is 30.05. In terms of profitability, DVAX's ROE is -0.08%, compared to TARO's ROE of +0.03%. Regarding short-term risk, DVAX is less volatile compared to TARO. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check TARO's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, COLL has a market cap of 1.4B. Regarding current trading prices, DVAX is priced at $15.50, while COLL trades at $45.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas COLL's P/E ratio is 27.52. In terms of profitability, DVAX's ROE is -0.08%, compared to COLL's ROE of +0.24%. Regarding short-term risk, DVAX is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check COLL's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, DVAX is priced at $15.50, while ALVO trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ALVO's P/E ratio is 18.35. In terms of profitability, DVAX's ROE is -0.08%, compared to ALVO's ROE of -0.26%. Regarding short-term risk, DVAX is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ALVO's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, AMPH has a market cap of 1.3B. Regarding current trading prices, DVAX is priced at $15.50, while AMPH trades at $28.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas AMPH's P/E ratio is 12.19. In terms of profitability, DVAX's ROE is -0.08%, compared to AMPH's ROE of +0.15%. Regarding short-term risk, DVAX is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check AMPH's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, EVO has a market cap of 1.2B. Regarding current trading prices, DVAX is priced at $15.50, while EVO trades at $3.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas EVO's P/E ratio is -6.36. In terms of profitability, DVAX's ROE is -0.08%, compared to EVO's ROE of -0.17%. Regarding short-term risk, DVAX is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check EVO's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, CRON has a market cap of 1B. Regarding current trading prices, DVAX is priced at $15.50, while CRON trades at $2.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas CRON's P/E ratio is 24.00. In terms of profitability, DVAX's ROE is -0.08%, compared to CRON's ROE of +0.03%. Regarding short-term risk, DVAX is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check CRON's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, PCRX has a market cap of 994.2M. Regarding current trading prices, DVAX is priced at $15.50, while PCRX trades at $23.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas PCRX's P/E ratio is 49.17. In terms of profitability, DVAX's ROE is -0.08%, compared to PCRX's ROE of +0.03%. Regarding short-term risk, DVAX is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check PCRX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, DVAX is priced at $15.50, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas PETQ's P/E ratio is 83.73. In terms of profitability, DVAX's ROE is -0.08%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, DVAX is less volatile compared to PETQ. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check PETQ's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, TLRY has a market cap of 764.4M. Regarding current trading prices, DVAX is priced at $15.50, while TLRY trades at $7.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas TLRY's P/E ratio is -0.32. In terms of profitability, DVAX's ROE is -0.08%, compared to TLRY's ROE of -1.14%. Regarding short-term risk, DVAX is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check TLRY's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ESPR has a market cap of 659.8M. Regarding current trading prices, DVAX is priced at $15.50, while ESPR trades at $3.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ESPR's P/E ratio is -6.19. In terms of profitability, DVAX's ROE is -0.08%, compared to ESPR's ROE of +0.25%. Regarding short-term risk, DVAX is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ESPR's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, EMBC has a market cap of 626M. Regarding current trading prices, DVAX is priced at $15.50, while EMBC trades at $10.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas EMBC's P/E ratio is 4.48. In terms of profitability, DVAX's ROE is -0.08%, compared to EMBC's ROE of -0.21%. Regarding short-term risk, DVAX is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check EMBC's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, IRWD has a market cap of 610M. Regarding current trading prices, DVAX is priced at $15.50, while IRWD trades at $4.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas IRWD's P/E ratio is 20.83. In terms of profitability, DVAX's ROE is -0.08%, compared to IRWD's ROE of -0.09%. Regarding short-term risk, DVAX is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check IRWD's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, CGC has a market cap of 591.7M. Regarding current trading prices, DVAX is priced at $15.50, while CGC trades at $1.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas CGC's P/E ratio is -0.84. In terms of profitability, DVAX's ROE is -0.08%, compared to CGC's ROE of -0.53%. Regarding short-term risk, DVAX is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check CGC's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, EBS has a market cap of 583.7M. Regarding current trading prices, DVAX is priced at $15.50, while EBS trades at $10.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas EBS's P/E ratio is 8.29. In terms of profitability, DVAX's ROE is -0.08%, compared to EBS's ROE of +0.14%. Regarding short-term risk, DVAX is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check EBS's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, DVAX is priced at $15.50, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas BDSI's P/E ratio is 6.82. In terms of profitability, DVAX's ROE is -0.08%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, DVAX is less volatile compared to BDSI. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check BDSI's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, KMDA has a market cap of 512.2M. Regarding current trading prices, DVAX is priced at $15.50, while KMDA trades at $8.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas KMDA's P/E ratio is 25.37. In terms of profitability, DVAX's ROE is -0.08%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, DVAX is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check KMDA's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ORGO has a market cap of 497.5M. Regarding current trading prices, DVAX is priced at $15.50, while ORGO trades at $3.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ORGO's P/E ratio is -49.00. In terms of profitability, DVAX's ROE is -0.08%, compared to ORGO's ROE of +0.00%. Regarding short-term risk, DVAX is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ORGO's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, SIGA has a market cap of 480.5M. Regarding current trading prices, DVAX is priced at $15.50, while SIGA trades at $6.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas SIGA's P/E ratio is 6.51. In terms of profitability, DVAX's ROE is -0.08%, compared to SIGA's ROE of +0.35%. Regarding short-term risk, DVAX is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check SIGA's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, AQST has a market cap of 394.2M. Regarding current trading prices, DVAX is priced at $15.50, while AQST trades at $3.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas AQST's P/E ratio is -5.67. In terms of profitability, DVAX's ROE is -0.08%, compared to AQST's ROE of +1.40%. Regarding short-term risk, DVAX is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check AQST's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, SNDL has a market cap of 383.7M. Regarding current trading prices, DVAX is priced at $15.50, while SNDL trades at $1.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas SNDL's P/E ratio is -5.73. In terms of profitability, DVAX's ROE is -0.08%, compared to SNDL's ROE of -0.08%. Regarding short-term risk, DVAX is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check SNDL's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, DVAX is priced at $15.50, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ALIM's P/E ratio is 5.28. In terms of profitability, DVAX's ROE is -0.08%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, DVAX is less volatile compared to ALIM. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ALIM's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, EOLS has a market cap of 280.7M. Regarding current trading prices, DVAX is priced at $15.50, while EOLS trades at $4.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas EOLS's P/E ratio is -4.81. In terms of profitability, DVAX's ROE is -0.08%, compared to EOLS's ROE of +4.83%. Regarding short-term risk, DVAX is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check EOLS's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, LFCR has a market cap of 273.1M. Regarding current trading prices, DVAX is priced at $15.50, while LFCR trades at $7.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas LFCR's P/E ratio is -5.74. In terms of profitability, DVAX's ROE is -0.08%, compared to LFCR's ROE of -2.33%. Regarding short-term risk, DVAX is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check LFCR's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, DVAX is priced at $15.50, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas LNDC's P/E ratio is -4.04. In terms of profitability, DVAX's ROE is -0.08%, compared to LNDC's ROE of -15.33%. Regarding short-term risk, DVAX is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check LNDC's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, DVAX is priced at $15.50, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas TYHT's P/E ratio is -1.61. In terms of profitability, DVAX's ROE is -0.08%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, DVAX is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check TYHT's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ACB has a market cap of 207M. Regarding current trading prices, DVAX is priced at $15.50, while ACB trades at $3.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ACB's P/E ratio is -3.35. In terms of profitability, DVAX's ROE is -0.08%, compared to ACB's ROE of +0.07%. Regarding short-term risk, DVAX is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ACB's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, DERM has a market cap of 197.1M. Regarding current trading prices, DVAX is priced at $15.50, while DERM trades at $8.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas DERM's P/E ratio is -24.43. In terms of profitability, DVAX's ROE is -0.08%, compared to DERM's ROE of -0.40%. Regarding short-term risk, DVAX is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check DERM's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, BGM has a market cap of 193.6M. Regarding current trading prices, DVAX is priced at $15.50, while BGM trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas BGM's P/E ratio is -3.33. In terms of profitability, DVAX's ROE is -0.08%, compared to BGM's ROE of -0.01%. Regarding short-term risk, DVAX is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check BGM's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, OGI has a market cap of 189.2M. Regarding current trading prices, DVAX is priced at $15.50, while OGI trades at $1.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas OGI's P/E ratio is 12.73. In terms of profitability, DVAX's ROE is -0.08%, compared to OGI's ROE of +0.05%. Regarding short-term risk, DVAX is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check OGI's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, DVAX is priced at $15.50, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas REPH's P/E ratio is -8.04. In terms of profitability, DVAX's ROE is -0.08%, compared to REPH's ROE of -0.22%. Regarding short-term risk, DVAX is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check REPH's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, DVAX is priced at $15.50, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas THTX's P/E ratio is -17.84. In terms of profitability, DVAX's ROE is -0.08%, compared to THTX's ROE of +0.38%. Regarding short-term risk, DVAX is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check THTX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, DVAX is priced at $15.50, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas SCTL's P/E ratio is -7.86. In terms of profitability, DVAX's ROE is -0.08%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, DVAX is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check SCTL's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, TKNO has a market cap of 110.3M. Regarding current trading prices, DVAX is priced at $15.50, while TKNO trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas TKNO's P/E ratio is -6.24. In terms of profitability, DVAX's ROE is -0.08%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, DVAX is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check TKNO's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, CRDL has a market cap of 110.1M. Regarding current trading prices, DVAX is priced at $15.50, while CRDL trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas CRDL's P/E ratio is -3.29. In terms of profitability, DVAX's ROE is -0.08%, compared to CRDL's ROE of -2.03%. Regarding short-term risk, DVAX is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check CRDL's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, DVAX is priced at $15.50, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas PROC's P/E ratio is 1.53. In terms of profitability, DVAX's ROE is -0.08%, compared to PROC's ROE of -2.22%. Regarding short-term risk, DVAX and PROC have similar daily volatility (0.00).Check PROC's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, DVAX is priced at $15.50, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas OPTN's P/E ratio is -4.42. In terms of profitability, DVAX's ROE is -0.08%, compared to OPTN's ROE of +0.47%. Regarding short-term risk, DVAX and OPTN have similar daily volatility (0.00).Check OPTN's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, DVAX is priced at $15.50, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ZOM's P/E ratio is -1.62. In terms of profitability, DVAX's ROE is -0.08%, compared to ZOM's ROE of -0.59%. Regarding short-term risk, DVAX is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ZOM's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, IXHL has a market cap of 94.5M. Regarding current trading prices, DVAX is priced at $15.50, while IXHL trades at $0.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas IXHL's P/E ratio is -0.37. In terms of profitability, DVAX's ROE is -0.08%, compared to IXHL's ROE of -1.99%. Regarding short-term risk, DVAX is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check IXHL's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, DVAX is priced at $15.50, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas GRVI's P/E ratio is 26.05. In terms of profitability, DVAX's ROE is -0.08%, compared to GRVI's ROE of -1.20%. Regarding short-term risk, DVAX is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check GRVI's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ALVOW has a market cap of 83.9M. Regarding current trading prices, DVAX is priced at $15.50, while ALVOW trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ALVOW's P/E ratio is N/A. In terms of profitability, DVAX's ROE is -0.08%, compared to ALVOW's ROE of -0.26%. Regarding short-term risk, DVAX is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ALVOW's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ASRT has a market cap of 77.3M. Regarding current trading prices, DVAX is priced at $15.50, while ASRT trades at $12.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ASRT's P/E ratio is -2.68. In terms of profitability, DVAX's ROE is -0.08%, compared to ASRT's ROE of -0.27%. Regarding short-term risk, DVAX is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ASRT's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, DVAX is priced at $15.50, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, DVAX's ROE is -0.08%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, DVAX is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ZYNE's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, DVAX is priced at $15.50, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas SSIC's P/E ratio is 11.93. In terms of profitability, DVAX's ROE is -0.08%, compared to SSIC's ROE of -0.00%. Regarding short-term risk, DVAX is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check SSIC's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, DVAX is priced at $15.50, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas VLNS's P/E ratio is -1.03. In terms of profitability, DVAX's ROE is -0.08%, compared to VLNS's ROE of N/A. Regarding short-term risk, DVAX is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check VLNS's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, DVAX is priced at $15.50, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas DRRX's P/E ratio is -4.44. In terms of profitability, DVAX's ROE is -0.08%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, DVAX and DRRX have similar daily volatility (0.00).Check DRRX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, CPIX has a market cap of 57.4M. Regarding current trading prices, DVAX is priced at $15.50, while CPIX trades at $3.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas CPIX's P/E ratio is -16.00. In terms of profitability, DVAX's ROE is -0.08%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, DVAX is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check CPIX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, DVAX is priced at $15.50, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas JUPW's P/E ratio is -2.41. In terms of profitability, DVAX's ROE is -0.08%, compared to JUPW's ROE of -0.99%. Regarding short-term risk, DVAX is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check JUPW's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, INCR has a market cap of 45.1M. Regarding current trading prices, DVAX is priced at $15.50, while INCR trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas INCR's P/E ratio is -1.65. In terms of profitability, DVAX's ROE is -0.08%, compared to INCR's ROE of -0.17%. Regarding short-term risk, DVAX is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check INCR's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ZYBT has a market cap of 41.8M. Regarding current trading prices, DVAX is priced at $15.50, while ZYBT trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ZYBT's P/E ratio is -14.70. In terms of profitability, DVAX's ROE is -0.08%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, DVAX is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ZYBT's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, DVAX is priced at $15.50, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas QLI's P/E ratio is -4.92. In terms of profitability, DVAX's ROE is -0.08%, compared to QLI's ROE of -0.16%. Regarding short-term risk, DVAX and QLI have similar daily volatility (0.00).Check QLI's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, RMTI has a market cap of 36.3M. Regarding current trading prices, DVAX is priced at $15.50, while RMTI trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas RMTI's P/E ratio is -5.12. In terms of profitability, DVAX's ROE is -0.08%, compared to RMTI's ROE of -0.17%. Regarding short-term risk, DVAX is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check RMTI's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, SCYX has a market cap of 32.3M. Regarding current trading prices, DVAX is priced at $15.50, while SCYX trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas SCYX's P/E ratio is -1.51. In terms of profitability, DVAX's ROE is -0.08%, compared to SCYX's ROE of -0.54%. Regarding short-term risk, DVAX is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check SCYX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, DVAX is priced at $15.50, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas HEXO's P/E ratio is -0.26. In terms of profitability, DVAX's ROE is -0.08%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, DVAX is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check HEXO's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, TXMD has a market cap of 26.4M. Regarding current trading prices, DVAX is priced at $15.50, while TXMD trades at $2.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas TXMD's P/E ratio is 228.00. In terms of profitability, DVAX's ROE is -0.08%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, DVAX is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check TXMD's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, DVAX is priced at $15.50, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas CYTH's P/E ratio is -0.80. In terms of profitability, DVAX's ROE is -0.08%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, DVAX and CYTH have similar daily volatility (0.00).Check CYTH's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, TLPH has a market cap of 19.3M. Regarding current trading prices, DVAX is priced at $15.50, while TLPH trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas TLPH's P/E ratio is -2.47. In terms of profitability, DVAX's ROE is -0.08%, compared to TLPH's ROE of -1.26%. Regarding short-term risk, DVAX is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check TLPH's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, DVAX is priced at $15.50, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas EVOK's P/E ratio is -7.97. In terms of profitability, DVAX's ROE is -0.08%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, DVAX and EVOK have similar daily volatility (0.00).Check EVOK's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, AYTU has a market cap of 18.4M. Regarding current trading prices, DVAX is priced at $15.50, while AYTU trades at $2.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas AYTU's P/E ratio is -0.66. In terms of profitability, DVAX's ROE is -0.08%, compared to AYTU's ROE of -1.07%. Regarding short-term risk, DVAX is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check AYTU's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, APUS has a market cap of 15.7M. Regarding current trading prices, DVAX is priced at $15.50, while APUS trades at $1.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas APUS's P/E ratio is -3.04. In terms of profitability, DVAX's ROE is -0.08%, compared to APUS's ROE of -1.40%. Regarding short-term risk, DVAX is less volatile compared to APUS. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check APUS's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, DVAX is priced at $15.50, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ACRX's P/E ratio is -0.31. In terms of profitability, DVAX's ROE is -0.08%, compared to ACRX's ROE of -1.26%. Regarding short-term risk, DVAX is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ACRX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, QNTM has a market cap of 13.6M. Regarding current trading prices, DVAX is priced at $15.50, while QNTM trades at $3.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas QNTM's P/E ratio is -0.37. In terms of profitability, DVAX's ROE is -0.08%, compared to QNTM's ROE of -3.85%. Regarding short-term risk, DVAX is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check QNTM's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, DVAX is priced at $15.50, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas AGRX's P/E ratio is -0.89. In terms of profitability, DVAX's ROE is -0.08%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, DVAX is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check AGRX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, COSM has a market cap of 10.3M. Regarding current trading prices, DVAX is priced at $15.50, while COSM trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas COSM's P/E ratio is -0.49. In terms of profitability, DVAX's ROE is -0.08%, compared to COSM's ROE of -0.74%. Regarding short-term risk, DVAX is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check COSM's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, BFRI has a market cap of 10.1M. Regarding current trading prices, DVAX is priced at $15.50, while BFRI trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas BFRI's P/E ratio is -0.58. In terms of profitability, DVAX's ROE is -0.08%, compared to BFRI's ROE of +29.95%. Regarding short-term risk, DVAX is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check BFRI's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, YCBD has a market cap of 9.5M. Regarding current trading prices, DVAX is priced at $15.50, while YCBD trades at $0.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas YCBD's P/E ratio is -0.83. In terms of profitability, DVAX's ROE is -0.08%, compared to YCBD's ROE of -0.15%. Regarding short-term risk, DVAX is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check YCBD's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, DVAX is priced at $15.50, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas NLTX's P/E ratio is -0.28. In terms of profitability, DVAX's ROE is -0.08%, compared to NLTX's ROE of -0.40%. Regarding short-term risk, DVAX is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check NLTX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, DVAX is priced at $15.50, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas LCI's P/E ratio is -0.04. In terms of profitability, DVAX's ROE is -0.08%, compared to LCI's ROE of +1.66%. Regarding short-term risk, DVAX is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check LCI's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, DVAX is priced at $15.50, while BGXX trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas BGXX's P/E ratio is -0.76. In terms of profitability, DVAX's ROE is -0.08%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, DVAX and BGXX have similar daily volatility (0.00).Check BGXX's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, DVAX is priced at $15.50, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas ADMP's P/E ratio is -0.08. In terms of profitability, DVAX's ROE is -0.08%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, DVAX is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check ADMP's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, GELS has a market cap of 6.3M. Regarding current trading prices, DVAX is priced at $15.50, while GELS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas GELS's P/E ratio is -1.36. In terms of profitability, DVAX's ROE is -0.08%, compared to GELS's ROE of -0.43%. Regarding short-term risk, DVAX is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check GELS's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, SBFM has a market cap of 5.6M. Regarding current trading prices, DVAX is priced at $15.50, while SBFM trades at $1.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas SBFM's P/E ratio is 0.22. In terms of profitability, DVAX's ROE is -0.08%, compared to SBFM's ROE of -0.25%. Regarding short-term risk, DVAX is less volatile compared to SBFM. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check SBFM's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, SNOA has a market cap of 4.9M. Regarding current trading prices, DVAX is priced at $15.50, while SNOA trades at $2.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas SNOA's P/E ratio is -1.46. In terms of profitability, DVAX's ROE is -0.08%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, DVAX is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check SNOA's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, DVAX is priced at $15.50, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas MNK's P/E ratio is -0.44. In terms of profitability, DVAX's ROE is -0.08%, compared to MNK's ROE of +0.11%. Regarding short-term risk, DVAX is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check MNK's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, DVAX is priced at $15.50, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas FLGC's P/E ratio is -0.19. In terms of profitability, DVAX's ROE is -0.08%, compared to FLGC's ROE of -0.82%. Regarding short-term risk, DVAX is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for DVAX.Check FLGC's competition here

DVAX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DVAX stands at 1.8B. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, DVAX is priced at $15.50, while GHSI trades at $3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DVAX currently has a P/E ratio of -41.89, whereas GHSI's P/E ratio is -0.79. In terms of profitability, DVAX's ROE is -0.08%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, DVAX and GHSI have similar daily volatility (0.00).Check GHSI's competition here